Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

COVID-19 survivors tracked for 3 years to uncover hidden health impacts

NCT ID NCT04411147

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 17, 2026 · Updated 10 times

Summary

This study follows 583 adults who recovered from COVID-19 or were close contacts. Researchers will track their health, mental well-being, and immune responses over 3 years to understand long-term effects and whether prior infection prevents reinfection. Participants undergo regular tests including blood work, lung function, and mental health interviews.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could reveal how long immunity lasts after COVID-19 and what long-term health problems survivors may face.
What could go wrong
This is an observational study, not a treatment trial. It may not find clear answers due to the complexity of long COVID and varying participant experiences.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

583 people

The number who actually took part.

Started

Jun 2020

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Primary Clinical

Ages

18 to 120 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA: In order to be eligible to participate in this study, all individuals must meet all of the following criteria: 1. Stated willingness to comply with all study procedures and availability for the duration of the study 2. Age 18 years or older. 3. Ability of participant to understand and the willingness to sign a written informed consent document. 4. Hemoglobin of 9.0 gm/dl or higher 5. Willingness to give consent for the storage of blood samples for research. 6. Have a physician or clinic outside NIH to manage underlying medical conditions or agreeing to establish care with an outside physician or clinic for any medical conditions requiring treatment that may be diagnosed as a result of protocol participation. COVID-19 Survivor Group 1. Documented prior COVID-19 as evidenced by: 1. detection of SARS-CoV-2 RNA or antigen in nasopharyngeal swab, sputum or other sample source with EUA/approval from the FDA; or 2. a positive antibody test using an assay that has received emergency use authorization (EUA) from the Food and Drug Administration (FDA) and a history clinical manifestation compatible with COVID-19. 2. Greater than 6 weeks since onset of COVID-19 symptoms and no fever for at least 1 week. For individuals with asymptomatic infection, screening will not occur until at least 4 weeks after the last positive SARS-CoV-2 PCR or antigen test. COVID-19 Close Contact 1. Living in the same household as a COVID-19 survivor during the time of illness or, being within approximately 6 feet (2 meters) of a COVID-19 case for a prolonged period of time or having direct contact with infectious secretions of a COVID-19 case (e.g., being coughed on). 2. No diagnosis of COVID-19 or current symptoms suggestive of COVID-19 EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: 1. Current abuse of alcohol or other drugs that, in the judgement of the Principal Investigator (PI) could interfere with patient compliance. 2. Inability to travel to the NIH Clinical Center for study visits 3. Any medical or mental health condition that, in the judgement of the PI, would make the volunteer unable to participate in the study. 4. Positive SARS-CoV-2 PCR at screening visit 5. Positive test for antibodies to SARS-CoV-2 nucleocapsid protein at the screening visit (control group only). 6. History of any of the following in the past 14 days: fever \> 38.2 degrees Celsius; new or worsening respiratory symptoms (e.g. cough, dyspnea). 7. Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.